Company: SUPN
Filing Date: 2025-02-04
Form Type: 8-K
Source: 0001356576-25-000004
Chunk: 0

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-04
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01

Other Events.

On February 4, 2025, Supernus Pharmaceuticals, Inc. (“ Supernus” or the “ Company”) issued a press release announcing the receipt of the final approval from the U. S. Food and Drug Administration (FDA) for SPN-830 (ONAPGO) for the continuous treatment of motor fluctuations (OFF episodes) in people with Parkinson’s disease (PD) not adequately controlled with oral levodopa and one or more adjunct PD medications.

A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.